AbbVie (NYSE:ABBV) Trading Up 1% – Time to Buy?

Shares of AbbVie Inc. (NYSE:ABBV) rose 1% during trading on Tuesday . The stock traded as high as $234.08 and last traded at $231.8320. Approximately 6,889,711 shares changed hands during mid-day trading, an increase of 7% from the average daily volume of 6,414,366 shares. The stock had previously closed at $229.51.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on ABBV shares. Morgan Stanley increased their price target on shares of AbbVie from $250.00 to $255.00 and gave the stock an “overweight” rating in a research note on Friday, August 1st. Citigroup lowered their target price on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research report on Monday, November 3rd. Raymond James Financial set a $256.00 target price on AbbVie in a report on Monday, November 3rd. Bank of America upped their price target on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Finally, Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the company an “overweight” rating in a research note on Thursday, October 9th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $241.85.

AbbVie Trading Down 1.8%

The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The company has a 50-day moving average price of $227.51 and a 200-day moving average price of $206.27. The company has a market capitalization of $402.20 billion, a price-to-earnings ratio of 108.37, a P/E/G ratio of 1.42 and a beta of 0.50.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a $1.73 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is currently 524.24%.

Hedge Funds Weigh In On AbbVie

Several large investors have recently bought and sold shares of ABBV. Ellenbecker Investment Group grew its position in AbbVie by 0.8% during the third quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock worth $1,235,000 after buying an additional 44 shares in the last quarter. Security National Bank of Sioux City Iowa IA lifted its position in shares of AbbVie by 0.3% in the 3rd quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock worth $3,562,000 after acquiring an additional 45 shares during the period. Matthew Goff Investment Advisor LLC lifted its position in shares of AbbVie by 0.3% in the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after acquiring an additional 45 shares during the period. Centennial Wealth Advisory LLC grew its holdings in shares of AbbVie by 2.2% during the 3rd quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock worth $484,000 after purchasing an additional 45 shares in the last quarter. Finally, Willner & Heller LLC increased its position in shares of AbbVie by 0.6% during the third quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock valued at $1,759,000 after purchasing an additional 46 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.